Research programme: cannabinoid CB2 receptor agonists - BTG

Drug Profile

Research programme: cannabinoid CB2 receptor agonists - BTG

Latest Information Update: 02 Feb 2011

Price : $50

At a glance

  • Originator BTG
  • Class Cannabinoids
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Multiple sclerosis; Neuropathic pain; Pain

Most Recent Events

  • 05 Mar 2004 Preclinical trials in Multiple sclerosis in USA (unspecified route)
  • 05 Mar 2004 Preclinical trials in Pain in USA (unspecified route)
  • 05 Mar 2004 Preclinical trials in Neuropathic pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top